Risultati della ricerca - David Russell‐Jones

Raffina i risultati
  1. 1
    Recent advances in incretin‐based therapies

    Recent advances in incretin‐based therapies di David Russell‐Jones, Stephen Gough

    Pubblicazione 2012
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Growth hormone and sport: abuse, potential benefits, and difficulties in detection.

    Growth hormone and sport: abuse, potential benefits, and difficulties in detection. di Marie Louise Healy, David Russell‐Jones

    Pubblicazione 1997
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Identification of barriers to insulin therapy and approaches to overcoming them

    Identification of barriers to insulin therapy and approaches to overcoming them di David Russell‐Jones, Frans Pouwer, Kamlesh Khunti

    Pubblicazione 2017
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men

    Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men di M. Denise Robertson, David Russell‐Jones, A. Margot Umpleby, Derk‐Jan Dijk

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Insulin X10 revisited: a super-mitogenic insulin analogue

    Insulin X10 revisited: a super-mitogenic insulin analogue di Bent Hansen, Peter Kurtzhals, Astrid B. Jensen, A. Dejgaard, David Russell‐Jones

    Pubblicazione 2011
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials

    Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials di David Russell‐Jones, M.‐A. Gall, M. Niemeyer, M. Diamant, Stefano Del Prato

    Pubblicazione 2015
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    Miscoding, misclassification and misdiagnosis of diabetes in primary care

    Miscoding, misclassification and misdiagnosis of diabetes in primary care di Simon de Lusignan, Norah Hassan Sadek, Henrietta Mulnier, Aumran Tahir, David Russell‐Jones, Kamlesh Khunti

    Pubblicazione 2011
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

    Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp di S. V. M. Hordern, Jonelle E. Wright, A. Margot Umpleby, Fariba Shojaee‐Moradie, J. Amiss, David Russell‐Jones

    Pubblicazione 2005
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes

    High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes di Marie Louise Healy, James Gibney, David Russell‐Jones, Claire Pentecost, P Croos, P H Sönksen, A. Margot Umpleby

    Pubblicazione 2003
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

    Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial di David Russell‐Jones, Allan Vaag, O. Schmitz, Bipin Sethi, Nebojša Lalić, Slobodan Antić, Marija Zdravković, Gabriela Martinez Ravn, Rafael Simó

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial di Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones

    Pubblicazione 2018
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes

    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes di Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Insulin-Sensitizing Effects on Muscle and Adipose Tissue after Dietary Fiber Intake in Men and Women with Metabolic Syndrome

    Insulin-Sensitizing Effects on Muscle and Adipose Tissue after Dietary Fiber Intake in Men and Women with Metabolic Syndrome di M. Denise Robertson, John W. Wright, Emmanuelle Loizon, Cyrille Debard, Hubert Vidal, Fariba Shojaee‐Moradie, David Russell‐Jones, A. Margot Umpleby

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

    Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) di David Russell‐Jones, Robert Cuddihy, M Hanefeld, Ajay Kumar, José Gerardo González‐González, Melanie Chan, Anne M. Wolka, Marilyn K. Boardman

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes

    Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes di Helen Simpson, Nicola Jackson, Fariba Shojaee‐Moradie, R. H. Jones, David Russell‐Jones, Peter H. Sönksen, David B. Dunger, A. Margot Umpleby

    Pubblicazione 2004
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK

    Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK di Harry Knights, Nikhil Mayor, Kristina Millar, Matthew Cox, Evgeniya Bunova, Morgan Hughes, Jack W. Baker, Sanju Mathew, David Russell‐Jones, Aleksandra Kotwica

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

    Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Tr... di Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell‐Jones, J. B. Larsen, Søren C. Tamer, Stephen C. Bain

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial

    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label,... di David Russell‐Jones, Tetsuya Babazono, Roman Cailleteau, Susanne Engberg, Concetta Irace, Maiken Ina Siegismund Kjaersgaard, Chantal Mathieu, Julio Rosenstock, Vincent Woo, David C. Klonoff

    Pubblicazione 2023
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes

    Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes di Philip Home, Paul B. Bartley, David Russell‐Jones, H Hanaire-Broutin, Jan‐Evert Heeg, Pascale Abrams, Mona Landin–Olsson, Birgitte Hylleberg, Hanne Lang, Eberhard Draeger

    Pubblicazione 2004
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Efficacy of increased resistant starch consumption in human type 2 diabetes

    Efficacy of increased resistant starch consumption in human type 2 diabetes di Caroline L. Bodinham, Lee Smith, E. Louise Thomas, Jimmy D. Bell, Jonathan R. Swann, Adele Costabile, David Russell‐Jones, A. Margot Umpleby, M. Denise Robertson

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: